Cotización Vortex Energy - VRTX

	Precios en Tiempo Real	Nivel 2
Forex

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

0.055

Postura de Compra

0.05

Postura de Venta

0.055

Volume Operado de la Acción

92,727

0.05 Rango del Día 0.055

0.05 Rango de 52 semanas 0.85

Precio Anterior

0.05

Precio de Apertura

0.055

Hora

2000

0.055

Última hora de negociación

12:36:49

Volumen promedio (3 m)

127,666

Volumen financiero

Precio Promedio Ponderado

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.005	-8.33333333333	0.06	0.06	0.05	118910	0.05350438	CS
4	-0.035	-38.8888888889	0.09	0.09	0.05	173710	0.060912	CS
12	-0.09	-62.0689655172	0.145	0.145	0.05	127666	0.08535349	CS
26	-0.165	-75	0.22	0.27	0.05	87018	0.12111039	CS
52	-0.355	-86.5853658537	0.41	0.85	0.05	155309	0.37262337	CS
156	-0.045	-45	0.1	2.32	0.05	199681	0.92090555	CS
260	-0.045	-45	0.1	2.32	0.05	199681	0.92090555	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
RBRumble Resources Inc	$ 0.35 (169.23%)	6.39k
VCVolatus Capital Corp	$ 0.01 (100.00%)	492k
BEEBee Vectoring Technologies International Inc	$ 0.01 (100.00%)	132k
OWLIOne World Lithium Inc	$ 0.025 (66.67%)	383.73k
TRAITrilogy AI Corp	$ 0.09 (63.64%)	36k
CURE.XBiocure Technology Inc	$ 0.01 (-66.67%)	3k
ENRTEnertopia Corp	$ 0.005 (-50.00%)	29.3k
MYCOMydecine Innovations Group Inc	$ 0.005 (-50.00%)	38k
ACRG.A.UAcreage Holdings Inc	US$ 0.005 (-50.00%)	220.51k
CLDVCloud3 Ventures Inc	$ 0.015 (-40.00%)	3.51M
SPMTSpearmint Resources Inc	$ 0.025 (25.00%)	4.15M
CLDVCloud3 Ventures Inc	$ 0.015 (-40.00%)	3.51M
CSSCascada Silver Corp	$ 0.04 (0.00%)	2.21M
PRMEPrime Drink Group Corp	$ 0.305 (-3.17%)	1.87M
MILIMilitary Metals Corp	$ 0.34 (-1.45%)	1.36M